Viracta Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Viracta Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Viracta Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Viracta Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Viracta Therapeutics Catalyst Calendar
Proactively evaluate Viracta Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Viracta Therapeutics Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Dec 2021 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 01 Dec 2021 | Phase I/II Trial Completion | Viracta Therapeutics Inc | VIRX | (nanatinostat + valganciclovir) | Immunology; Infectious Disease; Oncology | Anaplastic Large Cell Lymphoma (ALCL); Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy; Common Variable Immunodeficiency (CVID); Cutaneous T-Cell Lymphoma; Diffuse Large B-Cell Lymphoma; Epstein–Barr Virus (HHV-4) Infections; Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Human Immunodeficiency Virus (HIV) Infections (AIDS); Lymphoma; Lymphoproliferative Disorders; Natural Killer Cell Lymphomas; Peripheral T-Cell Lymphomas (PTCL); Post-Transplant Lymphoproliferative Disorder; Systemic Lupus Erythematosus; T-Cell Lymphomas; Unspecified B-Cell Lymphomas; Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) | Conferences |
| 30 Jun 2021 | IND Filing (US) | Viracta Therapeutics Inc | VIRX | VRx-510 | Oncology | Solid Tumor | Company Presentation |
| 30 Jun 2021 | IND Filing (US) | Viracta Therapeutics Inc | VIRX | VRx-510 | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) | Company Presentation |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer